Abstract

To date, there have been several systematic reviews with meta-analysis that have shown no reduction in mortality with the use of inhaled nitric oxide (iNO) in patients with acute respiratory distress syndrome (ARDS). Importantly, these reports fail to make a distinction between the pediatric and adult patient. The number of adult patients in these reviews are far greater than the number of pediatric patients, which makes it difficult to interpret the data regarding the role of iNO on the pediatric population. Extrapolating data from the adult population to the pediatric population is complicated as we know that physiology and the body’s response to disease can be different between adult and pediatric patients. iNO has been demonstrated to improve outcomes in term and near-term infants with hypoxic respiratory failure associated with pulmonary hypertension. Recently, Bronicki et al. published a prospective randomized control trial investigating the impact of iNO on the pediatric patient population with acute respiratory failure. In this study, a benefit of decreased duration of mechanical ventilation and an increased rate of ECMO-free survival was demonstrated in patients who were randomized to receiving iNO, suggesting that there may be benefit to the use of iNO in pediatric ARDS (PARDS) that has not been demonstrated in adults. iNO has repeatedly been shown to transiently improve oxygenation in all age groups, and yet neonates and pediatric patients have shown improvement in other outcomes that have not been seen in adults. The mechanism that explains improvement with the use of iNO in these patient populations are not well understood but does not appear to be solely a result of sustained improvement in oxygenation. There are physiologic studies that suggest alternative mechanisms for explaining the positive effects of iNO, such as platelet aggregation inhibition and reduction in systemic inflammation. Hence, the role of iNO by various mechanisms and in various age groups warrants further investigation.

Highlights

  • In many review articles of acute respiratory distress syndrome (ARDS), the conclusion that the use of inhaled nitric oxide (iNO) does not reduce mortality continues to be perpetuated

  • In many review articles of acute respiratory distress syndrome (ARDS), the conclusion that the use of iNO does not reduce mortality continues to be perpetuated. The references for this conclusion are the systematic reviews with meta analysis by Adhikari et al [1, 2] and Afshari et al [3] These are well conducted systematic reviews; the conclusion made from these studies as it pertains to pediatric ARDS (PARDS) could be challenged

  • Most have taken for granted that the answer regarding the benefit of iNO in PARDS exists when the question as it applies to pediatrics has never scientifically been evaluated

Read more

Summary

INTRODUCTION

In many review articles of acute respiratory distress syndrome (ARDS), the conclusion that the use of iNO does not reduce mortality continues to be perpetuated. The references for this conclusion are the systematic reviews with meta analysis by Adhikari et al [1, 2] and Afshari et al [3] These are well conducted systematic reviews; the conclusion made from these studies as it pertains to pediatric ARDS (PARDS) could be challenged

Role of iNO in the Management of PARDS
EPIDEMIOLOGY OF ARDS AND PARDS
HISTORY OF NO AND iNO
MECHANISMS OF NO AND iNO
ARDS AND iNO IN ADULTS
ARDS AND iNO IN PEDIATRICS
WHERE DO WE GO FROM HERE?
Findings
CONCLUSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.